EU regulators approve Novartis’ breast cancer combo
Piqray in combination with fulvestrant is the first treatment for tumours with a PIK3CA mutation
Read More
Tag: alpelisib
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
